Acute Myeloid Leukemia PDX Models

Most commercially available blood cancer patient-derived xenograft (PDX) models are transient in nature, and non-transferable through passages (not renewable), without disease symptoms or mortality. However, Crown Bioscience’s PDX models for blood cancer are permanent, and allow the study of disease recurrence after initial treatment challenge and the efficacy testing of novel agents against drug resistance. The Crown Bioscience acute myeloid leukemia (AML) PDX collection consists of several models, including models with patient-relevant mutations e.g. FLT3(+), IDH2 mutation. More